Contents

Search


angioendotheliomatosis

Etiology: - malignant phenotype most common - benign reactive variant (reactive angioendotheliomatosis is a rare, poorly defined disorder - etiololgy depends on offending disease Epidemiology: - 100 cases of malignant angioendotheliomatosis & ~40 cases reactive angioendotheliomatosis have been described worldwide Pathology: - proliferation of histiocytes within vascular lumina - sludging effect of circulating malignant lymphoid cells - secondary intravascular thrombi & obliteration of the vessels Laboratory: - complete blood count - anemia - thrombocytopenia - leukocyte count variable - peripheral blood smear - serum chemistries - serum LDH elevated - serum AST & serum ALT elevated - serum alkaline phosphatase elevated - cryofibrinogen in plasma may be elevated Management: - treat as B-cell lymphoma - prognosis - mortality 80% within 1 year (malignant form) - reactive angioendotheliomatosis has a good prognosis -regression common when underlying disease, if discovered, is successfully treated Notes: - classification of diffuse large B-cell lymphoma derived from Snomed (otherwise would be classified as B-cell lymphoma)

General

diffuse large B-cell lymphoma (DLBCL)

References

  1. Schwartz RA, Elston DM Medscape: Angioendotheliomatosis. http://emedicine.medscape.com/article/1085936-overview